TenNor’s research and development program on TNP-2092 for prosthetic joint infections (PJIs) has been published in the Journal of Medicinal Chemistry as a Drug Annotation article. Drug Annotations are by invitation only to showcase promising new drugs in clinical development.
Link to the article: http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.6b00485.
TNP-2092 is a dual-action molecule currently in clinical development for PJIs and other hard-to-treat infections. Previously, TenNor has successfully completed the single ascending dose (SAD) and multiple ascending dose (MAD) studies under an US IND. TenNor has recently developed a gastrointestinal (GI) tract site-specific oral formulation for the treatment of Helicobacter pylori and other GI tract infections. The GI program is in clinical development stage under a China IND.